This disclosure describes a peptide including a tau peptide, methods of making the peptide, and methods of using the peptide. In some embodiments, the peptide prevents the mislocalization of tau that leads to tau-mediated synaptic deficits. In some cases, the peptide includes a protein transduction domain. In some embodiments, the peptide may be administered to a subject is at risk of or exhibiting symptoms of Alzheimer's Disease, Parkinson's disease, chronic traumatic encephalopathy, and/or another tauopathy.
